Send this to a friend

Harvard Pilgrim inks asthma drug contract

Harvard Pilgrim, which has been selling group policies in Connecticut since 2014, said Wednesday that it has signed an outcomes-based agreement with drugmaker AstraZeneca.
Under the terms, the not-for-profit health insurer will cover the asthma and chronic obstructive pulmonary disease drug Symbicort.
If patient symptoms, including those that require medical intervention, are in line with those observed in a prev ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media